Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of mdv 3100丨cas 915087-33-1 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications of MDV 3100丨915087-33-1
|
Property |
Specification |
|
Appearance |
White crystalline powder |
|
Identification |
The HNMR spectrum conforms to standard |
|
Residue on Ignition |
0.1% max |
|
Loss on Drying |
0.5% max |
|
Single Impurities |
0.1% max |
|
Total Impurities |
0.5% max |
|
Particle Size |
D90 ≤ 10μm |
|
Assay |
99.5% min |
Transport Information of MDV 3100丨915087-33-1
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2933290090999 |
|
Stability & Reactivity |
Stable storage for 1 year. DMSO solution can be stored at -20 °C for up to 3 months. |
|
Storage |
-20 °C |
|
Condition to Avoid |
|
|
Package |
Introduction
MDV 3100丨915087-33-1, commonly known as Enzalutamide, is a nonsteroidal androgen receptor (AR) inhibitor used in the treatment of prostate cancer. It is a second-generation anti-androgen drug that effectively blocks androgen signaling, slowing or stopping cancer cell growth in castration-resistant prostate cancer (CRPC).
Applications of MDV 3100丨915087-33-1
1. Treatment of Prostate Cancer
Castration-Resistant Prostate Cancer (CRPC):
Used for treating metastatic and non-metastatic CRPC, particularly in patients who no longer respond to traditional androgen deprivation therapy (ADT).
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC):
Administered in combination with ADT for patients with advanced prostate cancer that is still hormone-sensitive.
2. Androgen Receptor Inhibition in Cancer Research
Preclinical and Clinical Studies:
Used in research for drug resistance mechanisms and combination therapies in prostate cancer treatment.
Potential Expansion to Other Cancers:
Investigated for use in breast cancer and other androgen-driven tumors.
Benefits of MDV 3100丨915087-33-1
1. Strong Androgen Receptor Blocking
● Prevents testosterone and dihydrotestosterone (DHT) from activating the androgen receptor, slowing tumor growth.
2. Improved Survival Rates in CRPC Patients
● Clinical trials show significant improvement in overall survival (OS) and progression-free survival (PFS).
3. Oral Administration for Patient Convenience
● Available as an oral medication, making it easier to administer compared to chemotherapy or intravenous treatments.
4. Alternative for Patients Resistant to Other Therapies
● Effective in patients who have failed previous anti-androgen therapies, including bicalutamide or abiraterone acetate.
Conclusion
MDV 3100丨915087-33-1 is a critical advancement in prostate cancer treatment, offering high efficacy, patient convenience, and extended survival benefits. It is widely used in CRPC and metastatic prostate cancer and continues to be explored for potential applications in other androgen-driven cancers.
